

Resource Summary Report

Generated by RRID on Aug 8, 2026

Leica: BOND RX Stainer

RRID:SCR_025548

Type: Tool

Proper Citation

Leica: BOND RX Stainer (RRID:SCR_025548)

Resource Information

URL: <https://www.leicabiosystems.com/ihc-ish/ihc-ish-instruments/bond-rx/>

Proper Citation: Leica: BOND RX Stainer (RRID:SCR_025548)

Description: Fully automated research stainer that automates staining step which ensures that microscope slides are produced with consistent, reproducible, and efficient way. Utilizes biological assay called immunohistochemistry. BOND RX model expands on the capabilities of IHC by including other assays.

Synonyms: BOND RX Stainer

Resource Type: instrument resource

Keywords: Leica, stainer, automate staining step, microscope slides, immunohistochemistry,

Resource Name: Leica: BOND RX Stainer

Resource ID: SCR_025548

Alternate IDs: Model_Number_BOND_RX

Record Creation Time: 20240730T053256+0000

Record Last Update: 20260808T190727+0000

Ratings and Alerts

No rating or validation information has been found for Leica: BOND RX Stainer.

No alerts have been found for Leica: BOND RX Stainer.

Data and Source Information

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kuribayashi T, et al. (2026) Clinical Characteristics and Spatial Transcriptome Analysis of Non-Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study. *Cancer research communications*, 6(2), 284.

Kastinen M, et al. (2026) Unraveling the Effects and Characteristics of Proliferating Tumor and Cytotoxic T Cells in Colorectal Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(2), 350.

O'Reilly C, et al. (2026) LRRC15-CAR T Cells for the Treatment of Osteosarcoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1557.

Pawar NR, et al. (2026) A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter SLC43A1 (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cells. *Molecular cancer therapeutics*.

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. *Cell reports. Medicine*, 7(7), 102922.

Xu X, et al. (2026) A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma. *Cancer research*, 86(15), 3666.

Tran B, et al. (2026) Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(14), 2850.

Pasquero S, et al. (2026) Targeting peptidyl-arginine deiminase 4 suppresses SARS-CoV-2 replication and modulates the inflammatory response. *iScience*, 29(3), 115038.

Shen F, et al. (2025) Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(21), 4543.

Navarro-Serer B, et al. (2025) P4HA1 Mediates Hypoxia-Induced Invasion in Human Pancreatic Cancer Organoids. *Cancer research communications*, 5(5), 881.

Ojanperä A, et al. (2025) Significance of Th1 and Th2 Cell Densities and Th1/Th2 Cytokine Profiles in Colorectal Cancer. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 34(11), 2032.

Benjamin JS, et al. (2025) 23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation. *Cancer research communications*, 5(3), 476.

van Ravensteijn SG, et al. (2025) Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(17), 3678.

Ellis JR, et al. (2025) Siglec Ligand Immunohistochemistry Reveals Association With Immune Exclusion and Survival. *Laboratory investigation; a journal of technical methods and pathology*, 105(10), 104203.

Collet L, et al. (2025) Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(15), 3317.

Sternberg C, et al. (2024) Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment. *Molecular cancer*, 23(1), 245.